- IVF provider Virtus Health (VRT) is resuming treatment at its clinics after the Australian Federal Government reinstated elective medical procedures earlier this week
- Virtus will reopen its clinics from April 27 and begin increasing pathology and testing staff as demand returns to normal levels
- While the COVID-19 pandemic remains a concern, consultations will be performed via telehealth services, and the company will provide novel coronavirus testing where appropriate
- Earlier this week, the company also recommenced operations in Denmark but its clinics in the U.K. and Ireland remain closed
- Virtus Health shares are down 2.51 per cent today, trading for $2.72 per share
IVF provider Virtus Health (VRT) is resuming treatments after the Australian Federal Government reinstated elective medical procedures earlier this week.
Previously, the company was forced to suspend services at its clinics when a country-wide ban on elective medical procedures came into effect earlier in the year.
The Federal Government brought in the measures to limit the spread of COVID-19 through the healthcare system and free up medical resources for essential medical care.
With new cases of COVID-19 dropping, the Federal Government has decided to reinstate the non-essential medical care throughout the country.
As a result, Virtus will reopen its clinics and recommence treatments from April 27. Meanwhile, Virtus will begin increasing pathology staffing levels, as demand for its services returns to normal.
The company’s specialists will continue to consult patients remotely, to ensure social distances remains at safe levels. Furthermore, Virtus Health clinics will now provide COVID-19 testing though its medical professionals.
The test will be provided when deemed appropriate by the company’s medical professionals and will return results within 24 hours.
Earlier this week, the company also recommenced operations in Denmark, after the Danish government lifted similar elective treatment bans.
However, clinics in Ireland and the U.K. will remain closed, while the COVID-19 community-transmission rate remains at unsafe levels.
Kate Munnings, Virtus Health Group CEO, is pleased to once again be offering treatments to the company’s patients.
“Our Australian patients have been eagerly awaiting today’s decision,” Kate said.
“With the suspension lifted, it means women and couples that need assistance in order to conceive can now restart treatment. We are pleased the Government recognise the needs of ARS patients and their desire to have a family,” she said.
Virtus Health shares are down 2.51 per cent today, trading for $2.72 per share at 11:17 am AEST.